Ron van Schaik
Ron van Schaik
Professor Pharmacogenetics, Erasmus
Verified email at erasmusmc.nl
TitleCited byYear
Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up
FH Schröder, J Hugosson, MJ Roobol, TLJ Tammela, M Zappa, V Nelen, ...
The Lancet 384 (9959), 2027-2035, 2014
10882014
Pharmacogenetics: from bench to byte—an update of guidelines
JJ Swen, M Nijenhuis, A de Boer, L Grandia, AH Maitland‐van der Zee, ...
Clinical Pharmacology & Therapeutics 89 (5), 662-673, 2011
7302011
Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR‐1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus
DA Hesselink, RHN van Schaik, IP Van Der Heiden, M van der Werf, ...
Clinical Pharmacology & Therapeutics 74 (3), 245-254, 2003
7262003
A multicenter study of [-2] pro-prostate specific antigen combined with prostate specific antigen and free prostate specific antigen for prostate cancer detection in the 2.0 to …
WJ Catalona, AW Partin, MG Sanda, JT Wei, GG Klee, CH Bangma, ...
The Journal of urology 185 (5), 1650-1655, 2011
3702011
CYP3A5 variant allele frequencies in Dutch Caucasians
RHN Van Schaik, IP Van Der Heiden, JN Van Den Anker, J Lindemans
Clinical chemistry 48 (10), 1668-1671, 2002
3462002
Genetic variation in the multidrug and toxin extrusion 1 transporter protein influences the glucose-lowering effect of metformin in patients with diabetes: a preliminary study
ML Becker, LE Visser, RHN Van Schaik, A Hofman, AG Uitterlinden, ...
Diabetes 58 (3), 745-749, 2009
2542009
Interpatient variability in the pharmacokinetics of the HIV non‐nucleoside reverse transcriptase inhibitor efavirenz: the effect of gender, race, and CYP2B6 polymorphism
D Burger, I Van Der Heiden, C La Porte, M Van Der Ende, P Groeneveld, ...
British journal of clinical pharmacology 61 (2), 148-154, 2006
2342006
Prostate-specific antigen (PSA) isoform p2PSA in combination with total PSA and free PSA improves diagnostic accuracy in prostate cancer detection
FH Jansen, RHN van Schaik, J Kurstjens, W Horninger, H Klocker, ...
European urology 57 (6), 921-927, 2010
2332010
Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for CYP3A5 genotype and tacrolimus dosing
KA Birdwell, B Decker, JM Barbarino, JF Peterson, CM Stein, W Sadee, ...
Clinical Pharmacology & Therapeutics 98 (1), 19-24, 2015
2312015
A New Functional CYP3A4 Intron 6 Polymorphism Significantly Affects Tacrolimus Pharmacokinetics in Kidney Transplant Recipients
L Elens, R Bouamar, DA Hesselink, V Haufroid, IP van der Heiden, ...
Clinical chemistry 57 (11), 1574-1583, 2011
2172011
Signature of recent historical events in the European Y-chromosomal STR haplotype distribution
L Roewer, PJP Croucher, S Willuweit, TT Lu, M Kayser, R Lessig, ...
Human genetics 116 (4), 279-291, 2005
2132005
Genetic variation in the organic cation transporter 1 is associated with metformin response in patients with diabetes mellitus
ML Becker, LE Visser, RHN Van Schaik, A Hofman, AG Uitterlinden, ...
The pharmacogenomics journal 9 (4), 242-247, 2009
1962009
Population pharmacokinetics of cyclosporine in kidney and heart transplant recipients and the influence of ethnicity and genetic polymorphisms in the MDR‐1, CYP3A4, and …
DA Hesselink, T van Gelder, RHN van Schaik, AHMM Balk, ...
Clinical Pharmacology & Therapeutics 76 (6), 545-556, 2004
1922004
A genome-wide association study of acenocoumarol maintenance dosage
M Teichert, M Eijgelsheim, F Rivadeneira, AG Uitterlinden, ...
Human molecular genetics 18 (19), 3758-3768, 2009
1652009
The prostate health index selectively identifies clinically significant prostate cancer
S Loeb, MG Sanda, DL Broyles, SS Shin, CH Bangma, JT Wei, AW Partin, ...
The Journal of urology 193 (4), 1163-1169, 2015
1622015
The role of pharmacogenetics in the disposition of and response to tacrolimus in solid organ transplantation
DA Hesselink, R Bouamar, L Elens, RHN Van Schaik, T Van Gelder
Clinical pharmacokinetics 53 (2), 123-139, 2014
1602014
A simple score for estimating the long-term risk of fracture in patients using oral glucocorticoids
TP van Staa, P Geusens, HAP Pols, C de Laet, HGM Leufkens, C Cooper
Qjm 98 (3), 191-198, 2005
1572005
Effect of a new functional CYP3A4 polymorphism on calcineurin inhibitors’ dose requirements and trough blood levels in stable renal transplant patients
L Elens, RH Van Schaik, N Panin, M De Meyer, P Wallemacq, D Lison, ...
Pharmacogenomics 12 (10), 1383-1396, 2011
1562011
Pharmacogenetic pathway analysis of docetaxel elimination
SD Baker, J Verweij, GA Cusatis, RH Van Schaik, S Marsh, SJ Orwick, ...
Clinical Pharmacology & Therapeutics 85 (2), 155-163, 2009
1552009
CYP3A4* 22: promising newly identified CYP3A4 variant allele for personalizing pharmacotherapy
L Elens, T Van Gelder, DA Hesselink, V Haufroid, RHN Van Schaik
Pharmacogenomics 14 (1), 47-62, 2013
1482013
The system can't perform the operation now. Try again later.
Articles 1–20